Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rush, Hannah L., Murphy, Laura, Morgans, Alicia K., Clarke, Noel W., Cook, Adrian D., Attard, Gerhardt, Macnair, Archie, Dearnaley, David P., Parker, Christopher C., Russell, J. Martin, Gillessen, Silke, Matheson, David, Millman, Robin, Brawley, Christopher D., Pugh, Cheryl, Tanguay, Jacob S., Jones, Robert J., Wagstaff, John, Rudman, Sarah, O'Sullivan, Joe M., Gale, Joanna, Birtle, Alison, Protheroe, Andrew, Gray, Emma, Perna, Carla, Tolan, Shaun, McPhail, Neil, Malik, Zaf I., Vengalil, Salil, Fackrell, David, Hoskin, Peter, Sydes, Matthew R., Chowdhury, Simon, Gilbert, Duncan C., Parmar, Mahesh K. B., James, Nicholas D., Langley, Ruth E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2022
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612717/
https://ncbi.nlm.nih.gov/pubmed/34757812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00728
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados